AVEO Pharmaceuticals — Investor Presentation (August 2017)
31 slides from AVEO Pharmaceuticals's investor presentation, Aug 10, 2017
Slide 1: AVEO Overview August 2017
AVEO Overview August 2017 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate,” “believe,” “estimate,”
Slide 3: Opportunities for Value Creation
Opportunities for Value Creation Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Partner TIVO-1 (1st Line RCC) SCCHN (Investigator) Esophageal Cancer TIVO-3 (U.S. Phase 3 Registration Study in RCC) TiNivo (+Opdivo® RCC) AML (Investigator) Oncology CHMP Recommendation for Approval 6/23/17 Non-O
Slide 4: Large and Growing RCC Opportunity
Large and Growing RCC Opportunity ~$1.7 Billion* ~$1.4 Billion* * Total RCC market includes all stages of disease and treatment options. Source: GlobalData Forecast 2023 Market opportunity expected to grow to >$3 billion in Europe and North America* Market needs: Uncompromised PFS combined with impr
Slide 5: Tivozanib Three Pillar Strategy in RCC
Tivozanib Three Pillar Strategy in RCC MAA Review TIVO-3 : Tivo v. Sorafenib US Regulatory Decision CHMP Recommendation for Approval NDA Review 2016 2017 2018 2019 2020 Ph 2 Expansion Potential NDA Filing 2H 2018 PFS Data/OS Trend Estimated 1Q 2018 Ph 1 Data Ph 1 Tivo + Opdivo® EU Regulatory Decisio
Slide 6: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1. Nakamura K et al. Cancer Res 2006;66:9134–9142. 2. Eskens FA et al. Clin Cancer Res 2011;17:
Slide 7: TIVO-1: Unsurpassed PFS, Unique Safety Profile in 1st Line RCC
1 Motzer, et. al. ESMO 2012 (COMPARZ): 1st Line study, sutent vs. votrient. 2 Hutson, et. al. Lancet Oncol 2013; 14: 1245; 1st line Phase 3 study vs sorafenib. 3 Motzer, et. al. JCO Oct 2013; 1st Line TIVO-1 Phase 3 study, tivozanib vs. sorafenib. 4 Choueri, et. al. ESMO 2016. Poor and Intermediate
Slide 8: Tivozanib is Well Tolerated, Potential Preferred TKI for PD-1 Combination
Tivozanib is Well Tolerated, and Has the Potential to Become the Preferred TKI for PD-1 Combination Therapy Single Agent Toxicity All grade (Gr 3/4) Sutent1 (n=548) Votrient1 (n=554) Inlyta5 (n=189) Nexavar3 (n=257) Lenvima4 (n=52) Cometriq2 (n=331) Tivozanib3 (n=259) Hypertension 30% (15%) 40% (4%)
Slide 9: Top Three Toxicities Relevant to Patients with Advanced RCC
Top Three Toxicities Relevant to Patients with Advanced RCC* *Wong M, et al. J Med Econ. 2012;28:1-10. Additional months of PFS benefit patients require to accept adverse events Nexavar >50% Sutent =50% Tivozanib <15% Sutent >60% Cometriq>55% Votrient=55% Tivozanib <20% Cometriq >70% Votrient >60% S
Slide 10: Favorable Tolerability vs. Approved TKIs in RCC
Favorable Tolerability vs. Approved TKIs in RCC Incidence (%) Incidence (%) Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 Dose Reductions Dose Interruptions Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 Cabozantinib5 Lenvatinib+Everolimus6 1. Motzer et.al. J
Slide 11: Tivozanib High Selectivity May Be a Significant Advantage
Tivozanib High Selectivity1 May Be a Significant Advantage ASCO 2017 – GU Oral Discussion2 Confidential Nakamura K et al. Cancer Res 2006;66:9134–9142. Courtesy of Dr. H. Hammers
Slide 12: Tivozanib Global Registration Strategy
Tivozanib Global Registration Strategy
Slide 13: EUSA Pharma Oncology Licensing Agreement
EUSA Pharma Oncology Licensing Agreement: Optimizes Post-Approval Economics CHMP Recommendation for Approval June 23, 2017 Recommendation based on TIVO-1 first line RCC Phase 3 EC approval decision ~67 days post-recommendation EC provides marketing authorization in 28 EU cos., Norway, Iceland and Li
Slide 14: 1st Line RCC Market Offers Commercial Opportunity in Europe
Source: EU5 data from Decision Resources RCC Report Feb 2017. EU data obtained by 50% bulking of EU5 data 1938 7827 13914 19325 19355 7839 13937 1940 19676 9596 15051 2903 56% 56% 72% 72% 25% 25% 64% 76% 30% 1st Line RCC Market Offers Significant Potential Commercial Opportunity for Tivozanib in Eur
Slide 15: TIVO-3 + TIVO-1: Supporting 1st and 3rd Line Indications in North America
TIVO-3 + TIVO-1: Designed to Support 1st and 3rd Line Indications in North America N = ~322 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI (not sorafenib) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and Tolerability for ITT Pro
Slide 16: Tivozanib Efficacy in VEGF TKI Refractory Setting
Tivozanib Efficacy in VEGF TKI Refractory Setting * n= 389; investigator assessed PFS; independent PFS = 4.8 mo vs. 3.4 mo, HR = 0.741 (p=0.011) **investigator assessed PFS ^cabozantinib USPI 1. Motzer et al Lancet Oncol 2013; 14: 552–62 2. Motzer et al Lancet Oncol 2014 3. Hutson et al ASCO 2015 4.
Slide 17: 1st Line and Expanding 3rd+ Line Markets in North America
Source: Decision Resources RCC Report Feb 2017 1st Line and Expanding 3rd+ Line Markets Offer Significant Potential Commercial Opportunity for Tivozanib in North America New Therapeutic Launches Expanding Third+ Line to ~10K patients by 2020 NA Royalties to KHK: low- to mid-teens on net sales TIVO-3
Slide 18: Safety Matters: PD-1 Combination Setting
Safety Matters: PD-1 Combination Setting
Slide 19: Rationale for Combining VEGF + PD-(L)1 Inhibitors
Rationale for Combining VEGF + PD-(L)1 Inhibitors Gunturi, McDermott Current Treatment Options in Oncology 2014 Plimack International Kidney Cancer Symposium 2014
Slide 20: Tivozanib Has Immunomodulatory Properties
Tivozanib has Immunomodulatory Properties: Regulatory T Cell Reduction May Enhance PD-1 Activity Pawlowski N et al. AACR 2013. Poster 3971. Regulatory T cells suppress or downregulate induction and proliferation of effector T cells (e.g. CD4 and CD8) P=0.034
Slide 21: Early Data for PD-1 + VEGF TKIs/CTLA4 Combinations
Early Data for the Combination of PD-1 +VEGF TKIs/CTLA4: Demonstrated Promising Responses with Challenging Toxicity 1 Atkins et. al., ESMO 2016 2 Larkin et. al., ASCO 2017, ~ 1 treatment related death 3 Atkins at.al., ASCO 2017 4 Apolo et.al, ASCO 2017 5 Taylor et.al, ESMO 2016 6 Hammers et. al., ES
Slide 22: TKI Dose Reductions to Manage AEs in PD-1 Combinations
Significant reductions of TKI dose to manage AEs have been recommended to safely combine some TKIs with PD-1s in RCC CaboNivo1: Cabo recommended dose reduction from 60 to 40mg Lenvatinib + Pembro2: Lenv recommended dose reduction 24 to 20mg Reduced Dose May Adversely Impact Efficacy 1 Apolo et. al.,
Slide 23: Phase 1/2 TiNivo Study
Phase 1/2 TiNivo Study Tivozanib (1.0 mg/day) QD/21 days + nivolumab 240 mg Q 2 weeks N = 6 ECOG PS ≤ 1 and life expectancy ≥ 3 months Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240 mg Q 2 weeks Further evaluate the antineoplastic activity and safety Phase 1* Phase 2 1.5 mg/day N = ~20 A Phase 1/
Slide 24: High Potential Value Pipeline Programs
High Potential Value Pipeline Programs
Slide 25: Ficlatuzumab (HGF inhibitor MAb)
Ficlatuzumab (HGF inhibitor MAb) A Favorable Profile to In-Class Antibodies High affinity (pM) and slow off-rate for HGF High potency (nM) inhibiting all biological activities of HGF, including autocrine/paracrine activation loops In vivo preclinical efficacy superior to in-class antibodies Patent T
Slide 26: Advancing Robust Pipeline Through Partnership
Advancing Robust Pipeline Through Partnership Milestone and royalty payments subject to the successful development and/or commercialization of the product *Subject to milestone payment & royalty payment obligations to SVH AV-380 (GDF-15 inhibitor MAb) Indication: cachexia Incidence: 5M+ in US alone
Slide 27: AV-353 in Pulmonary Arterial Hypertension
AV-353: 1st-in-class opportunity to address major unmet need in pulmonary arterial hypertension (PAH) as potential to be first drug with disease modifying properties Binding specificity to Notch 3 reduces risks of pan-Notch toxicities that have hampered competitors Large Market Opportunity 2014 sale
Slide 28: Financials and Portfolio Summary
Financials and Portfolio Summary
Slide 29: Financial Highlights
Financial Highlights $40.1M in cash and investments as of 2Q 2017 Cash on hand would fund planned operations into 4Q 2018* beyond TIVO-3 readout which is expected 1Q 2018 Potential near term milestones: EC marketing approval triggers $4M R&D reimbursement payment from EUSA $2M milestone per reimburs
Slide 30: Potential Corporate Milestones
Potential Corporate Milestones 2017 2018 Tivozanib CHMP recommendation for approval TIVO-3 PFS data/OS trend (1Q18) Development milestones for AV-380 Manufacturing transfer (2017) and re-initiation of AV-203 clinical dev. (2018) Phase 1 complete – data presentation in 2H 2017 TIVO-3 enrollment compl
Slide 31: AVEO Overview August 2017
AVEO Overview August 2017
AVEO Pharmaceuticals — Investor Presentation (August 2017) on 6ix